Citation, DOI, disclosures and article data
Citation:
Feger J, Bell D, Major adverse cardiovascular event. Reference article, Radiopaedia.org (Accessed on 24 Apr 2024) https://doi.org/10.53347/rID-84714
A major adverse cardiovascular event (MACE), forming part of the larger category of major adverse clinical events, refers to a combined or composite clinical endpoint that is used for outcome evaluations in clinical trials for cardiovascular research. A major adverse cardiovascular/clinical event is employed as a surrogate measure of the safety and effectiveness of a particular intervention.
In the context of percutaneous coronary interventions (PCI), a major adverse cardiovascular event has been defined as being one of the following 1,2:
Since there is no standard definition of other adverse cardiovascular outcomes as e.g. stroke, heart failure, recurrent angina 1,2.
History and etymology
The term MACE seems to have originated in the 1990s and was initially developed to relate primarily to percutaneous coronary interventions 1-3. Although the terms "adverse cardiac event" and "adverse clinical event" predated MACE by several years, the former first appearing as a trial endpoint in the early 1980s and the latter in the late 1980s 5,6.
-
1. Kip K, Hollabaugh K, Marroquin O, Williams D. The Problem With Composite End Points in Cardiovascular Studies. J Am Coll Cardiol. 2008;51(7):701-7. doi:10.1016/j.jacc.2007.10.034 - Pubmed
-
2. Poudel I, Tejpal C, Rashid H, Jahan N. Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-Elevation Myocardial Infarction? A Literature Review. Cureus. 2019;11(7):e5280. doi:10.7759/cureus.5280 - Pubmed
-
3. Hermans W, Foley D, Rensing B et al. Usefulness of Quantitative and Qualitative Angiographic Lesion Morphology, and Clinical Characteristics in Predicting Major Adverse Cardiac Events During and After Native Coronary Balloon Angioplasty. CARPORT and MERCATOR Study Groups. Am J Cardiol. 1993;72(1):14-20. doi:10.1016/0002-9149(93)90211-t - Pubmed
-
4. Choi B, Rha S, Yoon S, Choi C, Lee M, Kim S. Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population. J Am Heart Assoc. 2019;8(12):e010541. doi:10.1161/JAHA.118.010541 - Pubmed
-
5. Kumar A, Murray D, Hanna C et al. Comparative Study of Cephalexin Hydrochloride and Cephalexin Monohydrate in the Treatment of Skin and Soft Tissue Infections. Antimicrob Agents Chemother. 1988;32(6):882-5. doi:10.1128/aac.32.6.882 - Pubmed
-
6. Rangno R & Langlois S. Comparison of Withdrawal Phenomena After Propranolol, Metoprolol and Pindolol. Br J Clin Pharmacol. 1982;13(S2):345S-51S. doi:10.1111/j.1365-2125.1982.tb01939.x - Pubmed
Promoted articles (advertising)